MEDICAL FEE DISPUTE RESOLUTION FINDINGS AND DECISION

GENERAL INFORMATION

Requestor Name

Respondent Name

Memorial Compounding Pharmacy

New Hampshire Insurance Company

MFDR Tracking Number

Carrier's Austin Representative

M4-17-0677-01

Box Number 19

MFDR Date Received

November 7, 2016

REQUESTOR'S POSITION SUMMARY

Requestor's Position Summary: "Memorial Compounding Pharmacy has made numerous attempts to have the attached bills processed. Broadspire has yet to approve or deny our bills. Broadspire has not sent Memorial Compounding Pharmacy any type of correspondence, EOB, or payments on any of the attached bills."

Amount in Dispute: \$3,046.65

RESPONDENT'S POSITION SUMMARY

Respondent's Position Summary: "Payment has been made for date of service 11/16/15. We are attaching the EOB and pay history. For the remaining dates of services of 7/29/16, 8/16/16, 8/30/16 and 1/29/16 payment has been denied due to no preauthorization."

Response Submitted by: Broadspire

SUMMARY OF FINDINGS

Dates of Service	Disputed Services	Amount In Dispute	Amount Due
November 16, 2015 – August 30, 2016	Pharmacy Services - Compounds	\$3,046.65	\$1,827.99

FINDINGS AND DECISION

This medical fee dispute is decided pursuant to Texas Labor Code §413.031 and applicable rules of the Texas Department of Insurance, Division of Workers' Compensation.

Background

- 1. 28 Texas Administrative Code §133.307 sets out the procedures for resolving medical fee disputes.
- 2. 28 Texas Administrative Code §134.502 sets out the procedures for pharmaceutical benefits.
- 3. 28 Texas Administrative Code §134.503 sets out the fee guidelines for pharmaceutical services.
- 4. 28 Texas Administrative Code §134.530 sets out the closed formulary requirements for claims not subject to certified networks.

- 5. The insurance carrier reduced payment for the disputed services with the following claim adjustment codes:
 - 39 Denied Medication Not Authorized

<u>Issues</u>

- 1. Is Memorial Compounding Pharmacy (Memorial) eligible for additional payment for date of service November 16, 2015?
- 2. Is the insurance carrier's reason for denial of payment supported?
- 3. Is Memorial entitled to reimbursement for the compounds in question?

Findings

- 1. Memorial is seeking reimbursement of \$609.33 for a compound dispensed on November 16, 2015. Review of the submitted documentation finds that New Hampshire Insurance Company reimbursed the full requested amount to Memorial on or about November 16, 2015. No additional reimbursement is recommended for this date of service.
- 2. Memorial is also seeking reimbursement of \$2,437.32 for compounds dispensed on January 29, 2016; July 29, 2016; August 16, 2016; and August 30, 2016. New Hampshire Insurance Company denied the disputed compound with claim adjustment reason code 39 "Denied Medication Not Authorized."
 - 28 Texas Administrative Code §134.530(b)(2) states that preauthorization is only required for:
 - drugs identified with a status of "N" in the current edition of the ODG Treatment in Workers' Comp
 (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates;
 - any compound that contains a drug identified with a status of "N" in the current edition of the ODG
 Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and
 any updates; and
 - any investigational or experimental drug for which there is early, developing scientific or clinical evidence demonstrating the potential efficacy of the treatment, but which is not yet broadly accepted as the prevailing standard of care as defined in Labor Code §413.014(a).

The division finds that the compounds in question do not include a drug identified with a status of "N" in the current edition of the ODG, *Appendix A*. New Hampshire Insurance Company failed to articulate any arguments to support its denial for preauthorization. Therefore, the division concludes that the compound in question did not require preauthorization and New Hampshire Insurance Company's denial of payment for this reason is not supported. Therefore, the disputed compound will be reviewed for reimbursement.

- 3. 28 Texas Administrative Code §134.502(d)(2) requires that compound drugs "be billed by listing each drug included in the compound and calculating the charge for each drug separately." The division finds that the submitted documentation does not support that Memorial billed the compound drug dispensed on January 29, 2016, in accordance with 28 Texas Administrative Code §134.502(d)(2). Therefore, this date of service is not eligible for reimbursement.
 - 28 Texas Administrative Code §134.503 applies to the compounds in dispute and states, in pertinent part:
 - (c) The insurance carrier shall reimburse the health care provider or pharmacy processing agent for prescription drugs the lesser of:
 - (1) the fee established by the following formulas based on the average wholesale price (AWP) as reported by a nationally recognized pharmaceutical price guide or other publication of pharmaceutical pricing data in effect on the day the prescription drug is dispensed:
 - (A) Generic drugs: ((AWP per unit) x (number of units) x 1.25) + \$4.00 dispensing fee per prescription = reimbursement amount;
 - (B) Brand name drugs: ((AWP per unit) x (number of units) x 1.09) + \$4.00 dispensing fee per prescription = reimbursement amount;
 - (C) When compounding, a single compounding fee of \$15 per prescription shall be added to the calculated total for either paragraph (1)(A) or (B) of this subsection; or

- (2) notwithstanding §133.20(e)(1) of this title (relating to Medical Bill Submission by Health Care Provider), the amount billed to the insurance carrier by the:
 - (A) health care provider; or
 - (B) pharmacy processing agent only if the health care provider has not previously billed the insurance carrier for the prescription drug and the pharmacy processing agent is billing on behalf of the health care provider.

The compounds dispensed on dates of service July 29, 2016; August 16, 2016; and August 30, 2016, were billed by listing each drug included in the compound and calculating the charge for each drug separately as required by 28 Texas Administrative Code §134.502(d)(2). Each ingredient is listed below with its corresponding reimbursement amount as applicable.

Ingredient	NDC &	Price/	Total	AWP Formula	Billed Amt	Lesser of
	Туре	Unit	Units	§134.503(c)(1)	§134.503	(c)(1) and
					(c)(2)	(c)(2)
Compound Fee	NA	\$15.00	NA	\$15.00	\$15.00	\$15.00
Versapro Cream	38779252903	\$3.20	40.8	\$142.31	\$102.00	\$102.00
	Brand Name		gm			
Ethoxy Diglycol	38779190301	\$0.342	4.2	\$1.80	\$1.44	\$1.44
	Generic		ml			
Amitriptyline	38779018904	\$18.24	1.8	\$41.04	\$31.63	\$31.63
HCl	Generic		gm			
Bupivacaine HCl	38779052405	\$45.60	1.2	\$68.40	\$48.02	\$48.02
	Generic		gm			
Gabapentin USP	38779246109	\$59.85	3.6	\$269.33	\$188.10	\$188.10
	Generic		gm		\$100.1U	\$100.1U
Amantadine HCl	38779041105	\$24.225	3.0	\$90.84	\$38.46	\$38.46
	Generic	324.22J	gm			
Baclofen	38779038809	\$35.63	5.4	\$240.50	\$184.68	\$184.68
	Generic		gm			
					Total	\$609.33
					х3	\$1,827.99

The total reimbursement is therefore \$1,827.99. This amount is recommended.

Conclusion

For the reasons stated above, the Division finds that the requestor has established that additional reimbursement is due. As a result, the amount ordered is \$1,827.99.

ORDER

Based on the submitted information, pursuant to Texas Labor Code Section 413.031 and 413.019 (if applicable), the division has determined the requestor is entitled to additional reimbursement for the disputed services. The division hereby ORDERS the respondent to remit to the requestor \$1,827.99, plus applicable accrued interest per 28 Texas Administrative Code §134.130, due within 30 days of receipt of this order.

Authorized Signature

	Laurie Garnes	December 21, 2017
Signature	Medical Fee Dispute Resolution Officer	Date

YOUR RIGHT TO APPEAL

Either party to this medical fee dispute has a right to seek review of this decision in accordance with Rule §133.307, effective May 31, 2012, 37 Texas Register 3833, applicable to disputes filed on or after June 1, 2012.

A party seeking review must submit a **Request to Schedule a Benefit Review Conference to Appeal a Medical Fee Dispute Decision** (form **DWC045M**) in accordance with the instructions on the form. The request must be received by the division within **twenty** days of your receipt of this decision. The request may be faxed, mailed or personally delivered to the division using the contact information listed on the form or to the field office handling the claim. The party seeking review of the MFDR decision shall deliver a copy of the request to all other parties involved in the

The party seeking review of the MFDR decision shall deliver a copy of the request to all other parties involved in the dispute at the same time the request is filed. **Please include a copy of the** *Medical Fee Dispute Resolution Findings* and **Decision** together with any other required information specified in 28 Texas Administrative Code §141.1(d).

Si prefiere hablar con una persona en español acerca de ésta correspondencia, favor de llamar a 512-804-4812.